Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer

H R Büller, T A Boon, C P Henny

    The Journal of Urology
    |July 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE.

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2023
    Same author

    Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
    Same author

    Venous thromboembolism in cancer patients: a population-based cohort study.

    Blood·2020
    Same author

    Thromboembolic and bleeding complications in patients with oesophageal cancer.

    The British journal of surgery·2020
    Same author

    Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

    Thrombosis research·2020
    Same author

    Perioperative bridging of anticoagulation: towards a more reserved approach.

    The Netherlands journal of medicine·2019
    Same journal

    On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

    The Journal of urology·2026
    Same journal

    Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

    The Journal of urology·2026
    Same journal

    Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

    The Journal of urology·2026
    Same journal

    The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

    The Journal of urology·2026
    Same journal

    Let's Shift the Focus from Death to Life after Fournier's Gangrene.

    The Journal of urology·2026
    Same journal

    Endourology and Nephrolithiasis.

    The Journal of urology·2026
    See all related articles

    Estrogen therapy for prostate cancer significantly lowers plasma antithrombin III activity, increasing risk for blood clots. Monitoring antithrombin III levels during treatment is crucial.

    Area of Science:

    • Oncology
    • Hematology
    • Pharmacology

    Background:

    • Estrogen therapy is used for prostate cancer treatment.
    • Estrogen therapy can affect coagulation factors.
    • Antithrombin III (ATIII) is a key regulator of coagulation.

    Purpose of the Study:

    • To investigate the effect of estrogen therapy on plasma antithrombin III activity in prostate cancer patients.
    • To assess the risk of thromboembolic complications associated with estrogen-induced ATIII deficiency.

    Main Methods:

    • Plasma ATIII activity was measured in 22 prostate cancer patients undergoing estrogen therapy.
    • Patients received either a loading dose (15 mg/day) or maintenance dose (1 mg/day) of diethylstilbestrol.
    • ATIII activity levels were compared to normal ranges (0.80-1.40 U/ml).

    Related Experiment Videos

    Main Results:

    • A loading dose of 15 mg/day diethylstilbestrol markedly decreased mean ATIII activity to 0.24 U/ml.
    • Patients on maintenance therapy (approx. 1 mg/day) showed normal ATIII levels.
    • Lower baseline ATIII levels in patients may lead to acquired ATIII deficiency and increased thromboembolic risk.

    Conclusions:

    • High-dose estrogen therapy significantly reduces plasma ATIII activity in prostate cancer patients.
    • Monitoring ATIII levels before and during estrogen therapy is recommended to mitigate thromboembolic risks.
    • Lower doses of estrogen may not significantly impact ATIII levels, suggesting a dose-dependent effect.